Christian Rolfo (@ChristianRolfo) ranks #38 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 4 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: KRASCENDO-1. CMS Open Payments lists $16,504 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #38 · 4 physicians engaged
- Presented at WCLC 2026, ASCO 2026, ESMO 2026 in 2026
- CMS Open Payments lists $16,504 in 2025 general payments.
This Month
What Christian Rolfo has posted in the last 30 days. Updated November 10, 2026.
Divarasib is improving the existing data in PFS , OS and ORR in KRAS G12C NSCLC in the Krascendo 1 trial. A really good news for our patients! Congrats @FSkoulidis & team! Simultaneous publication in @NEJM Excellent discussion @BenjaminBesseMD @KRASKickers @myESMO #ESMO26 https://t.co/trgiiEnUeQ
Who Amplifies Christian Rolfo
Physicians who reposted Christian Rolfo’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #38 | — | 4 | 4 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Christian Rolfo presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Mini oral (MO05.03)Analysis of MTAP loss prevalence between tissue and liquid NSCLC biopsiesSource: @HHorinouchi on X ↗
- WCLC 2026 · PresentationCONCORDANCE-2: liquid biopsy vs tissue concordance for EGFR in stage III NSCLCSource: @RobertoBoreaMD on X ↗
- ASCO 2026 · Trial in progressS1900J: amivantamab SC in NSCLC with MET amplification as primary driver (SWOG/Lung-MAP)Source: @christianrolfo on X ↗
- ESMO 2026 · Invited lecture (Educational session: Challenge your Expert)Use of liquid biopsies in early drug development: Are we ready for it?Source: @HHorinouchi on X ↗
What Colleagues Are Saying About Christian Rolfo
2026 posts by fellow physicians that mention @ChristianRolfo, quoted word for word.
🔬 Our work on whole-transcriptome profiling for metastatic recurrence prediction in early-stage NSCLC will be presented as an oral presentation at #WCLC2026 in Seoul. Grateful to @ChristianRolfo for his mentorship in advancing precision oncology. @OSUCCC_James @IASLC https://t.co/tea6SOG59Y
🆙#WCLC26 #LCSM Mini Oral Session 🔥Analysis of MTAP Loss Prevalence Between Tissue and Liquid NSCLC Biopsies 🎙️ @ChristianRolfo 🔢MO05.03 🎯MTAP Loss Prevalence 16.3% in Tissue (n=93,968) vs 2.5% in Liquid Biopsy Overall (n=21,598) 🎯Liquid Detection Approaches Tissue Rates at TF≥10-20% 🔗 https://t.co/DP9QiGMyrq @OncoAlert @Larvol @IASLC
It is fashion week at #AACR26! The best dressed Onc docs at AACR- @ChristianRolfo and Dr Tina Cascone @UTMDAnderson https://t.co/R8P80KShAX
Trials Christian Rolfo Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| KRASCENDO-1 | 1 | #15 of 49 | Oct 25, 2026 |
Christian Rolfo on KRASCENDO-1
Divarasib is improving the existing data in PFS , OS and ORR in KRAS G12C NSCLC in the Krascendo 1 trial. A really good news for our patients! Congrats @FSkoulidis & team! Simultaneous publication in @NEJM Excellent discussion @BenjaminBesseMD @KRASKickers @myESMO #ESMO26 https://t.co/trgiiEnUeQ
Christian Rolfo’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Excellent #AACR26 Plenary on MRD. Outstanding presentation by @landau_lab guiding us on the ctDNA journey in MRD. @AACR @AACRPres @isliquidbiopsy https://t.co/cDfQKseF1B
Very interesting discussion and presentation of #TimaCascone @UTMDAnderson in the NeoCOAST Association of cDNA clearance with clinical outcomes AT #ESMO26 @myESMO @isliquidbiopsy https://t.co/sIh0k3MoAK
Very interesting Liquid Biopsy Mini Symposium #AACR26 Important study from Tim Burns, @lpstabile ,and colleagues showing divergence between NSCLC primary tumors and brain metastasis. Using ctDNA pair pre & post craniotomy. collaboration @OSUCCC_James @UPMC @isliquidbiopsy https://t.co/OXQMZ7fSWq
Interesting presentation on profiling treatment IO related pneumonitis.RNAseq TCR seq data. Congrats @DrJNaidoo and all the team!! #ESMO26 @myESMO https://t.co/cXTRVrS59o
Very proud of our great faculty at @OhioStateMedOnc !! Congrats @MateusTrinconi ! @OSUCCC_James @ASCO #ASCO26 https://t.co/S4PRiwlQVu
Industry Payments
CMS Open Payments · 2025 general payments
$16,504 across 18 payments